Cantor Fitzgerald initiated coverage on Eikon Therapeutics
$EIKN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2026 | Overweight | Cantor Fitzgerald | |
| 3/2/2026 | $32.00 | Overweight | Morgan Stanley |
| 3/2/2026 | $29.00 | Overweight | Analyst |
| 3/2/2026 | $26.00 | Outperform | Mizuho |
| 3/2/2026 | $34.00 | Buy | BofA Securities |
| 2/26/2026 | $7.00 | Underperform | Wedbush |
8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
10-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
Cantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight
Morgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00
Analyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates. "2025 was an important year of progress for Eikon's business and clinical programs," said Roger M. Perlmutter, M.D., Ph.D., Chief Execut